Loading
A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT03424005 by Hoffmann-La Roche, with 1132 participants planned, started 2018-03-30 and due to reach its primary completion in 2030-09-30. Interventions recorded: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab and Chemotherapy (Gemcitabine + Carboplatin or Eribulin).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Gilead Sciences (incl. Kite), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipatasertib, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Carboplatin and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/